Despite improvements in HLA typing, graft-versus-host disease (GVHD) contin
ues to impair the results after volunteer unrelated donor bone marrow trans
plantation (VUD-BMT) in adult patients compared with matched sibling BMT. H
ere, the outcome after VUD-BMT using a specific regimen with high-dose anti
-T-lymphocyte globulin (ATG) was analysed. Fifty-five adult patients, media
n age 34 years (range 17-55 years), with acute or chronic leukaemia or myel
odysplastic syndrome (MDS) were transplanted in first complete remission (C
R1)/first chronic phase (CP1) (early disease) (n = 21) or in advanced (CR2/
CP2, no remission) disease (n = 34) from an unrelated marrow donor. GVHD pr
ophylaxis consisted of ATG-S (Fresenius) 60-90 mg/kg b.w. prior to transpla
ntation, in addition to cyclosporin A and short-course methotrexate. Graft
failure did not occur and white brood cell count (WBC) >1.0 x 10(9)/l was r
eached at median day +16. The cumulative incidence of acute (a)GVHD grade I
I-IV was 15% [95% CI (8%, 28%)] and of chronic GVHD was 51% [95% CI (38%, 6
8%)]. The cumulative incidence of relapse within 1 year was 0% [95% CI (0%,
19%)] and 21% [95% CI (11%, 40%)] for patients with early and advanced dis
ease respectively. With a median follow-up of 28 months (range 16-45 months
), 2-year disease-free and overall survival for patients transplanted in CR
1/CP1 was 81% and 81% [95% CI (64%, 98%)], respectively and for patients wi
th advanced disease was 33% [95% CI(17%, 50%)] and 40% [95% CI (23%, 57%)]
respectively. Complete and persistent donor chimaerism was seen in 77.5% of
40 patients evaluated. All 14 chronic myeloid leukaemia (CML)-CP1 patients
became bcr-abl negative within 250 d. High-dose ATG pretransplant results
in a low incidence of severe aGVHD without compromising donor chimaerism or
elimination of minimal residual disease. Our results are similar to data o
btained after matched sibling donor transplantation.